Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerPolicy UpdatesOphthalmology/OptometryBlue Cross Blue Shield NC Amniotic Membrane Covera…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - North CarolinaPolicy N/A

    Amniotic Membrane and Amniotic Fluid Injections for Ophthalmic Indications

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - North Carolina policy alerts

    Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines coverage and medical necessity criteria for human amniotic membrane grafts and states investigational status for injections of amniotic fluid and particulated amniotic membrane for ophthalmic indications; applies to BCBS North Carolina providers and members.

    Policy Summary
    PayerBlue Cross Blue Shield - North Carolina
    PolicyAmniotic Membrane and Amniotic Fluid Injections for Ophthalmic Indications
    Policy CodePolicy N/A
    Change TypeRoutine review — no material changes
    Effective DateJul 15, 2026
    Last ReviewJul 15, 2026
    Next Review DateOct 1, 2025
    Key ActionObtain prior authorization and verify member benefits before submitting requests for human amniotic membrane grafts.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    9+ophthalmic indications listed as medically necessary for HAM grafts
    investigationalinjection of human amniotic fluid for all indications
    DEWS 3-4dry eye severity level for which HAM grafts may be considered

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    multiple RCTs
    evidence base summarized across indications
    Codes listedbilling/coding guidance present

    Coverage and Medical Necessity Criteria

    Initial Therapy Coverage

    Covered when the following indication-specific criteria are met

    HAM graft indications

    • Neurotrophic keratitis with ocular surface damage and inflammation that does not respond to conservative therapy (see Policy Guidelines).conservative therapy failed

      See Policy Guidelines for examples of conservative therapy duration and modalities.

    • Corneal ulcers and melts that do not respond to initial conservative therapy (see Policy Guidelines).conservative therapy failed
    • Corneal perforation with active inflammation after corneal transplant: Corneal perforation when there is active inflammation after corneal transplant requiring adjunctive treatment.

      Sutured or glued HAM may be used when indicated.

    • Bullous keratopathy (palliative): Bullous keratopathy as a palliative measure in patients who are not candidates for curative treatment (eg, endothelial or penetrating keratoplasty).
    • Partial limbal stem cell deficiency with extensive diseased tissue where selective removal alone is not sufficient.
    • Moderate or severe Stevens-Johnson syndrome.
    • Persistent epithelial defects that do not respond to conservative therapy (see Policy Guidelines).conservative therapy failed
    • Severe dry eye (DEWS 3 or 4) with ocular surface damage and inflammation that remains symptomatic after Steps 1, 2, and 3 of the dry eye disease management algorithm (see Policy Guidelines).failed steps 1-3 of TFOS/DEWS management algorithm

      Placement of self-retained HAM for 2–11 days has been associated with symptom reduction and surface restoration in trials and series.

    • Moderate or severe acute ocular chemical burn.
    • Use with suture or glue (specific situations): Human amniotic membrane grafts with suture or glue may be considered medically necessary for: corneal perforation when corneal tissue is not immediately available; and pterygium repair when there is insufficient healthy tissue to create a conjunctival autograft.

    Not Medically Necessary / Investigational

    Investigational uses: Human amniotic membrane grafts and products not listed as medically necessary for ophthalmic indications are considered investigational. Injection of micronized or particulated human amniotic membrane is investigational for all indications. Injection of human amniotic fluid is investigational for all indications.

    For wound and burn indications, see related policy 'Skin and Soft Tissue Substitutes.'

    When Covered (selected ophthalmic indications)

    Covered when evidence and clinical input support HAM use for the following ophthalmic conditions:

    Severe dry eye with ocular surface damage and inflammation: Placement of human amniotic membrane (eg, self-retained HAM) is covered for severe dry eye with ocular surface damage and inflammation that does not respond to conservative therapy; clinical evidence includes an RCT (20 patients) and a retrospective series (84 patients, 97 eyes) showing symptom reduction and surface restoration up to 3 months.conservative therapy failed

    Clinical input supported use and evidence judged sufficient to determine meaningful improvement in net health outcome.

    Moderate or severe acute ocular chemical burns: HAM transplantation plus medical therapy may be covered for moderate or severe acute ocular chemical burns; evidence includes three RCTs (total 197 patients). Two RCTs did not show faster epithelial healing, but clinical input supports HAM and evidence was judged sufficient to result in meaningful improvement in net health outcome.moderate or severe burn

    Relevant outcomes include symptoms, morbid events, functional outcomes, and QOL.

    When Not Covered / Investigational

    Not covered or investigational uses explicitly stated in policy history and guidelines:

    Micronized/particulated HAM or human amniotic fluid injections: Injection of micronized or particulated human amniotic membrane, and injection of human amniotic fluid, are considered investigational for all indications.any indication

    This position is reiterated in policy history and reference sections.

    HAM products and indications not listed as covered: All other human amniotic membrane products and ophthalmic indications not listed as medically necessary in this policy are considered investigational. Historical statements previously labeled some self‑retained HAM without suture (eg, Prokera®, AmbioDisk™) as investigational; current policy clarifies covered uses for selected self‑retained products as listed under covered indications.

    See policy history entries (2016–2018) for prior statements and coding updates.

    This policy addresses the use of human amniotic membrane (HAM) grafts and injections of amniotic-derived products specifically for ophthalmic indications. This policy does not address use of amniotic products for wounds or burns; those indications are handled under a related policy (see "Skin and Soft Tissue Substitutes"). Providers should refer to the separate wound/burn policy for coverage criteria and coding when treating non‑ophthalmic wounds or burns. (See also the policy history noting prior cross‑references and coding changes.)

    Injection of micronized or particulated human amniotic membrane is classified as investigational for all indications. The policy explicitly lists micronized/particulated HAM injections as investigational and excludes them from coverage for ophthalmic and non‑ophthalmic uses (for example, osteoarthritis and plantar fasciitis). Historical policy history entries reiterate this investigational stance and document its inclusion since policy inception.

    The policy distinguishes between particulate/injectable HAM products and HAM grafts or self‑retained HAM devices: while certain HAM grafts or self‑retained HAM products may be considered medically necessary for specified ophthalmic indications, micronized/particulated HAM injections remain investigational and are not covered.

    Injection of human amniotic fluid is considered investigational for all indications and is not covered. The policy explicitly states that injectable amniotic fluid products are investigational across indications, and this exclusion has been reiterated in the policy language and history.

    Because amniotic fluid is being investigated for injectable therapeutic use but lacks sufficient evidence for safety and effectiveness in ophthalmic indications, claims for injections of human amniotic fluid should be treated as investigational and not reimbursed under this policy.

    Billing, Codes, and Related Guidance

    Covered example productsmixedCovered
    Prokera®Self-retained amniotic membrane graft (example product referenced)
    AmbioDisk™Amniotic membrane graft (example product referenced)
    Applicable service codesCPT
    65778Application of amniotic membrane to ocular surface, per document 'Applicable service codes'
    65779Application of amniotic membrane to ocular surface, per document 'Applicable service codes'
    65780Application of amniotic membrane to ocular surface, per document 'Applicable service codes'
    Conservative therapy duration thresholds — examples of durations/prerequisites before HAM
    Neurotrophic keratitisConservative therapy trial of 5 days (eg, pressure patching, therapeutic contact lens, topical lubricants, topical antibiotics)
    Corneal ulcers and meltsConservative therapy trial of 2 days (eg, patching, therapeutic contact lens, topical antimicrobial agents)
    Persistent epithelial defectConsidered persistent if failed to close after 5 days of conservative treatment or shows no decrease in size after 2 days; initial conservative treatments include topical lubricants, topical antibiotics, therapeutic contact lens, or patching for 5 days
    Dry eye (DEWS 3–4) prerequisitesPrior steps 1–3 of staged management per TFOS/DEWS should be attempted before HAM for severe disease (DEWS 3–4; Schirmer <5 mm/5 min)

    Provider Responsibilities, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization recommended for HAM grafts

    Human amniotic membrane grafts (eg, Prokera®, AmbioDisk™) may be considered medically necessary for specified ophthalmic indications; providers should obtain prior authorization per BCBSNC requirements and verify benefit coverage before performing these procedures.

    Billing Rule

    Billing codes and administrative policy requirements

    Applicable service codes include CPT codes 65778, 65779, and 65780; inclusion of a code does not guarantee reimbursement and providers must follow BCBSNC Administrative Policies for reimbursement guidance.

    • Applicable service codes: 65778, 65779, 65780
    • Refer to BCBSNC Administrative Policies (www.bcbsnc.com) for reimbursement and billing rules

    Clinical Background and Rationale

    Human amniotic membrane (HAM) is the innermost lining of the amniotic sac composed of the amnion and chorion that is harvested after birth and processed (eg, cryopreserved or dehydrated) for use as an allograft. HAM contains collagen, fibronectin, hyaluronic acid, growth factors, cytokines, and anti-inflammatory proteins (for example, interleukin‑1 receptor antagonist) and has been reported to have anti‑inflammatory, antifibroblastic, and antimicrobial properties. HAM is considered largely nonimmunogenic, and processed products retain regenerative potential; these biological properties underlie the clinical use of HAM as grafts or patches for ocular surface disorders.

    Definitions

    Human amniotic membrane (HAM) — definition and processing (cryopreserved/dehydrated)
    DefinitionHuman amniotic membrane (HAM) is the innermost lining of the amniotic sac comprised of amnion and chorion, harvested immediately after birth and prepared as an allograft
    Processing methodsHAM is cleaned, sterilized, and either cryopreserved or dehydrated for clinical use
    Product formatsAvailable as patches, grafts, or self-retained devices (eg, contact-lens–like inserts) for ocular surface application
    Amniotic fluid — definition and investigational use for injections
    DefinitionAmniotic fluid is the fluid surrounding the fetus containing proteins, peptides, lipids, enzymes, hormones, and fetal cells
    Biologic contentsContains growth factors, hyaluronan and components comparable to synovial fluid (eg, lubrican, cytokines) under investigation for therapeutic effects
    Policy Summary
    PayerBlue Cross Blue Shield - North Carolina
    PolicyAmniotic Membrane and Amniotic Fluid Injections for Ophthalmic Indications
    Policy CodePolicy N/A
    Change TypeRoutine review — no material changes
    Effective DateJul 15, 2026
    Last ReviewJul 15, 2026
    Next Review DateOct 1, 2025
    Key ActionObtain prior authorization and verify member benefits before submitting requests for human amniotic membrane grafts.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaBilling, Codes, and Related GuidanceProvider Responsibilities, Prior Authorization, and DocumentationClinical Background and RationaleDefinitions
    Corneal perforation when corneal tissue not immediately available: Sutured HAM may be used as a temporary measure for corneal perforation when corneal transplant tissue is not immediately available; evidence is limited but clinical input supports temporary use as an adjunct to standard care.corneal tissue unavailable

    Standard treatment remains corneal transplantation.

    Pterygium repair when insufficient healthy conjunctiva: Sutured or glued HAM may be considered when there is insufficient healthy tissue to create a conjunctival autograft (eg, extensive, double, or recurrent pterygium); systematic reviews show conjunctival/limbal autograft is more effective at reducing recurrence, but HAM is acceptable in these limited situations.insufficient healthy conjunctiva

    Evidence includes RCTs and systematic reviews; clinical input supports selective use.

    Step Therapy

    Attempt and document required conservative therapies and durations

    The policy requires specific conservative therapy attempts and minimum durations for several indications before considering HAM grafts; document that conservative therapy failed per the policy thresholds.

    • Neurotrophic keratitis: example conservative therapy includes 5 days of pressure patching, therapeutic contact lens, topical lubricants, and topical antibiotics
    • Corneal ulcers/melts: initial conservative therapy may include 2 days of patching, therapeutic contact lens, and topical antimicrobials
    • Persistent epithelial defect: failed to close after 5 days of conservative treatment or no decrease after 2 days
    Note

    Include indication-specific clinical rationale with requests

    When submitting requests or performing procedures, include indication-specific details and a concise clinical rationale tied to the policy’s covered indications to support medical necessity determinations.

    • State the specific covered indication (eg, neurotrophic keratitis, severe DEWS 3–4, corneal perforation)
    • Explain why conservative therapy was inadequate or why HAM is required (eg, corneal tissue unavailable, insufficient conjunctiva for autograft)
    Documentation Required

    Verify member benefits before applying policy

    Verify member benefits and refer to the Member's Benefit Booklet for availability of benefits prior to applying this policy; member benefit design may affect coverage.

    Documentation Required

    Provide complete medical necessity documentation when records are requested

    When medical records are requested for medical necessity review, include all specific clinical information needed (eg, prior conservative treatments, durations, response) — letters of support alone are not sufficient unless they contain all required details.

    • Include documentation of prior conservative therapies and duration
    • Include clinical findings supporting the covered indication and reason HAM is needed
    • Letters of support may be helpful but must include all specific information required for determination
    Denial Risk

    Avoid nonlisted indications — investigational status

    Use of amniotic membrane grafts for ophthalmic indications not specifically listed as medically necessary in this policy will be considered investigational and may be denied.

    Denial Risk

    Medical records may be requested and codes do not ensure payment

    BCBSNC may request medical records to determine medical necessity; the presence of a listed code does not guarantee reimbursement.

    Investigational useInjection of human amniotic fluid is considered investigational for all indications (including ophthalmic) and is not covered
    Nonhealing — definition used in policy (<20% decrease in wound area over 2 weeks)
    Policy definitionNonhealing is defined as less than a 20% decrease in wound area with standard wound care for at least 2 weeks